The safety of lincomycin in pregnancy.
The progeny of mothers treated with lincomycin during the first, second, or third trimester of their pregnancy were extensively evaluated at various periods extending to 7 years after birth. As compared to a control group (mothers not receiving lincomycin), the study group did not show any more developmental anomalies of the teeth, specific physical defects, general developmental anomalties, or late developing abnormalities in speech, emotional and mental make-up, or ability to adjust to schooling, than would occur in the normal population. The relationship to clindamycin, a closely related derivative, and to antibiotic therapy during pregnancy is discussed.
D000014:Abnormalities, Drug-Induced; D000124:Achievement; D002648:Child; D002657:Child Development / Q000187:drug effects*; D002675:Child, Preschool; D003731:Dental Caries / Q000453:epidemiology; D004644:Emotions; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005500:Follow-Up Studies; D006128:Growth / Q000187:drug effects; D006309:Hearing / Q000187:drug effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007360:Intelligence / Q000187:drug effects; D007804:Language Development; D008034:Lincomycin / Q000009:adverse effects*; D008297:Male; D009048:Motor Skills / Q000187:drug effects; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D014075:Tooth Discoloration; D014785:Vision, Ocular / Q000187:drug effects
D008034:Lincomycin